BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 22562097)

  • 1. Apoptosis-inducing effect of the DR5 monoclonal antibody, D-6, alone or in combination with cisplatin, on A2780 ovarian cancer cells.
    Jiang Q; Zhu H; Liang B; Huang Y; Li C
    Mol Med Rep; 2012 Aug; 6(2):316-20. PubMed ID: 22562097
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumoricidal activity of combining the agonistic DR5 antibody D-6 with cisplatin in C30 cisplatin-resistant ovarian cancer in vitro and in vivo.
    Huang Y; Liang B; Jiang Q; Chen C; Yang K; Li C; Zheng A
    Mol Med Rep; 2014 Jul; 10(1):183-90. PubMed ID: 24789319
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhanced antitumor efficacy of a DR5-specific TRAIL variant over recombinant human TRAIL in a bioluminescent ovarian cancer xenograft model.
    Duiker EW; de Vries EG; Mahalingam D; Meersma GJ; Boersma-van Ek W; Hollema H; Lub-de Hooge MN; van Dam GM; Cool RH; Quax WJ; Samali A; van der Zee AG; de Jong S
    Clin Cancer Res; 2009 Mar; 15(6):2048-57. PubMed ID: 19276284
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-tumor activity of TRA-8 anti-death receptor 5 (DR5) monoclonal antibody in combination with chemotherapy and radiation therapy in a cervical cancer model.
    Straughn JM; Oliver PG; Zhou T; Wang W; Alvarez RD; Grizzle WE; Buchsbaum DJ
    Gynecol Oncol; 2006 Apr; 101(1):46-54. PubMed ID: 16271751
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structural and functional analysis of the interaction between the agonistic monoclonal antibody Apomab and the proapoptotic receptor DR5.
    Adams C; Totpal K; Lawrence D; Marsters S; Pitti R; Yee S; Ross S; Deforge L; Koeppen H; Sagolla M; Compaan D; Lowman H; Hymowitz S; Ashkenazi A
    Cell Death Differ; 2008 Apr; 15(4):751-61. PubMed ID: 18219321
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination of novel DR5 targeting agonistic scFv antibody TR2-3 with cisplatin shows enhanced synergistic antitumor activity in vitro and in vivo.
    Lei G; Xu M; Xu Z; Lu C; Tan S
    Biomed Pharmacother; 2018 Feb; 98():271-279. PubMed ID: 29272788
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-tumor activity of an anti-DR5 monoclonal antibody, TRA-8, in combination with taxane/platinum-based chemotherapy in an ovarian cancer model.
    Bevis KS; McNally LR; Sellers JC; Della Manna D; Londoño Joshi A; Amm H; Straughn JM; Buchsbaum DJ
    Gynecol Oncol; 2011 Apr; 121(1):193-9. PubMed ID: 21211830
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Noninvasive monitoring of pharmacodynamics and kinetics of a death receptor 5 antibody and its enhanced apoptosis induction in sequential application with doxorubicin.
    Weber TG; Pöschinger T; Galbán S; Rehemtulla A; Scheuer W
    Neoplasia; 2013 Aug; 15(8):863-74. PubMed ID: 23908588
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of human colon cancer xenografts with TRA-8 anti-death receptor 5 antibody alone or in combination with CPT-11.
    Oliver PG; LoBuglio AF; Zinn KR; Kim H; Nan L; Zhou T; Wang W; Buchsbaum DJ
    Clin Cancer Res; 2008 Apr; 14(7):2180-9. PubMed ID: 18381960
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-tumor activity of the TRA-8 anti-DR5 antibody in combination with cisplatin in an ex vivo human cervical cancer model.
    Kendrick JE; Straughn JM; Oliver PG; Wang W; Nan L; Grizzle WE; Stockard CR; Alvarez RD; Buchsbaum DJ
    Gynecol Oncol; 2008 Mar; 108(3):591-7. PubMed ID: 18177927
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synergistic induction of apoptosis by the combination of trail and chemotherapy in chemoresistant ovarian cancer cells.
    Cuello M; Ettenberg SA; Nau MM; Lipkowitz S
    Gynecol Oncol; 2001 Jun; 81(3):380-90. PubMed ID: 11371126
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Additive effect of sirolimus and anti-death receptor 5 agonistic antibody against hepatocellular carcinoma.
    Kawahara T; Toso C; Yamaguchi K; Cader S; Douglas DN; Nourbakhsh M; Lewis JT; Churchill TA; Yagita H; Kneteman NM
    Liver Int; 2013 Oct; 33(9):1441-8. PubMed ID: 23895107
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Molecular mechanism of cisplatin to enhance the ability of TRAIL in reversing multidrug resistance in gastric cancer cells].
    Zhu X; Zhang K; Wang Q; Chen S; Gou Y; Cui Y; Li Q
    Zhonghua Zhong Liu Za Zhi; 2015 Jun; 37(6):404-11. PubMed ID: 26463141
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug-induced caspase 8 upregulation sensitises cisplatin-resistant ovarian carcinoma cells to rhTRAIL-induced apoptosis.
    Duiker EW; Meijer A; van der Bilt AR; Meersma GJ; Kooi N; van der Zee AG; de Vries EG; de Jong S
    Br J Cancer; 2011 Apr; 104(8):1278-87. PubMed ID: 21487429
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cisplatin and a potent platinum(IV) complex-mediated enhancement of TRAIL-induced cancer cells killing is associated with modulation of upstream events in the extrinsic apoptotic pathway.
    Vondálová Blanárová O; Jelínková I; Szöor A; Skender B; Soucek K; Horváth V; Vaculová A; Andera L; Sova P; Szöllosi J; Hofmanová J; Vereb G; Kozubík A
    Carcinogenesis; 2011 Jan; 32(1):42-51. PubMed ID: 21037225
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The essential role of the mitochondria-dependent death-signaling cascade in chemotherapy-induced potentiation of Apo2L/TRAIL cytotoxicity in cultured thoracic cancer cells: amplified caspase 8 is indispensable for combination-mediated massive cell death.
    Nguyen DM; Yeow WS; Ziauddin MF; Baras A; Tsai W; Reddy RM; Chua A; Cole GW; Schrump DS
    Cancer J; 2006; 12(4):257-73. PubMed ID: 16925970
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treating metastatic solid tumors with bortezomib and a tumor necrosis factor-related apoptosis-inducing ligand receptor agonist antibody.
    Shanker A; Brooks AD; Tristan CA; Wine JW; Elliott PJ; Yagita H; Takeda K; Smyth MJ; Murphy WJ; Sayers TJ
    J Natl Cancer Inst; 2008 May; 100(9):649-62. PubMed ID: 18445820
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Caspase-dependent molecular mechanisms of anti-human DR5 monoclonal antibody mDRA-6 inducing apoptosis of human leukemia Jurkat cells.
    Du YW; Liu GC; Wang J; Zhao YP; Li SL; Chen JG; Jiang Q; Cai J; Ma YF
    Ai Zheng; 2009 Feb; 28(2):112-6. PubMed ID: 19550122
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tanshinone IIA Facilitates TRAIL Sensitization by Up-regulating DR5 through the ROS-JNK-CHOP Signaling Axis in Human Ovarian Carcinoma Cell Lines.
    Chang CC; Kuan CP; Lin JY; Lai JS; Ho TF
    Chem Res Toxicol; 2015 Aug; 28(8):1574-83. PubMed ID: 26203587
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination of ciglitazone, a peroxisome proliferator-activated receptor gamma ligand, and cisplatin enhances the inhibition of growth of human ovarian cancers.
    Yokoyama Y; Xin B; Shigeto T; Mizunuma H
    J Cancer Res Clin Oncol; 2011 Aug; 137(8):1219-28. PubMed ID: 21681689
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.